The Claim
In adults with type 2 diabetes, once-daily subcutaneous liraglutide at doses of 0.6, 1.2, and 1.8 mg reduces postprandial plasma glucose levels by 25-35% compared to placebo over five hours after a standardized meal, due to enhanced insulin secretion and delayed gastric emptying.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, daily injections of liraglutide at doses of 0.6, 1.2, or 1.8 mg lower blood glucose levels after meals by 25-35% compared to a placebo, through increased insulin release and slower stomach emptying.
See the scientific wording
In adults with type 2 diabetes, once-daily subcutaneous liraglutide at doses of 0.6, 1.2, and 1.8 mg significantly reduces postprandial plasma glucose levels by 25-35% compared to placebo, as measured over five hours after a standardized meal, likely due to enhanced insulin secretion and delayed gastric emptying, which are key mechanisms for improving glycemic control after meals.
Liraglutide binds to receptors in the pancreas and stomach, causing the pancreas to release more insulin after meals and slowing down how fast food leaves the stomach. This means sugar from food enters the bloodstream more slowly and more insulin is available to remove it, resulting in lower blood sugar spikes after eating.
What the research says
1 studyThis study found that a daily liraglutide shot lowered blood sugar spikes after meals by 25–35% in people with type 2 diabetes, just like the claim says — and it did so by helping the body release more insulin and slowing down digestion.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.